Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Language
Publication year range
1.
Vasc Endovascular Surg ; 55(6): 601-611, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33657926

ABSTRACT

BACKGROUND: COVID-19 is characterized by a pulmonary interstitial compromise which can require intensive care unit (ICU) and mechanical ventilation. Covid patients develop a wide range of pathologies. This study aims to identify the impact of COVID-19 in diseases commonly treated by vascular surgeons. METHODS: Four conditions were selected: venous thromboembolism (VTE), pulmonary embolism (PE), peripheral arterial disease (PAD), and microangiopathy. A systematic review of the literature using PRISMA guidelines was. RESULTS: Out of 1195 papers reviewed for conditions in COVID-19 patients relevant to routine vascular surgery practice, 43 papers were included and analyzed. Venous thrombosis was found to be the most common COVID-19 associated pathology with a cumulative incidence of 25% at 7 days and 48% at 14 days. Additionally, D-dimer levels proved to be a good predictor, even in the early stages of the disease with a sensitivity of 85%, specificity of 88.5% and a negative predictive value of 94.7%. Patients in the ICU demonstrated a significantly higher risk of developing VTE, even when receiving pharmacologic thromboprophylaxis. Although evidence of arterial thrombosis was less common (1% to 16.3%), its consequences were typically more serious, including limb loss and death even in young individuals (OR = 25, 95% CI). Finally, microangiopathy has a wide spectrum of clinical presentations from retinal microangiopathy to other more severe manifestations such as myocardial injury, pulmonary compromise and potential multiple organ dysfunction syndrome. CONCLUSIONS: Although the pathophysiological pathway by which COVID-19 produces thrombosis is not completely clear, the incidence of both arterial and venous thrombosis is increased. D-dimer screening should be done in all COVID-19 patients, as a predictor of thrombotic complications.


Subject(s)
COVID-19/complications , Peripheral Arterial Disease/epidemiology , Pulmonary Embolism/epidemiology , Thrombotic Microangiopathies/epidemiology , Vascular Surgical Procedures/statistics & numerical data , Venous Thromboembolism/epidemiology , Humans , Peripheral Arterial Disease/surgery , Peripheral Arterial Disease/virology , Pulmonary Embolism/surgery , Pulmonary Embolism/virology , Thrombotic Microangiopathies/surgery , Thrombotic Microangiopathies/virology , Venous Thromboembolism/surgery , Venous Thromboembolism/virology
4.
Ann Hepatol ; 16(4): 514-520, 2017.
Article in English | MEDLINE | ID: mdl-28611268

ABSTRACT

BACKGROUND/OBJECTIVES: Hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis. As a result of chronic inflammatory response to the virus, HCV-infected patients may be at a higher risk of venous thromboembolism (VTE). However, the data on this association is unclear. This systematic review and meta-analysis was conducted with the aims to summarize all available evidence. MATERIAL AND METHODS: A literature search was performed using MEDLINE and EMBASE from inception to April 2016. Studies that reported relative risks, odd ratios, or hazard ratios comparing the risk of VTE among HCV-infected patients vs. subjects without HCV infection were included. Pooled risk ratios (RR) and 95% confidence interval (CI) were calculated using a random-effect, generic inverse variance method. RESULTS: Three studies met our eligibility criteria and were included in analysis. The pooled RR of VTE in HCV-infected patients vs. subjects without HCV infection was 1.38 (95% CI, 1.08-1.77, I2 = 40%). Subgroup analysis showed that risk was increased for both pulmonary embolism (PE) and deep venous thrombosis (DVT) even though without adequate power to demonstrate statistical significance (Pooled RR of 1.34, 95% CI, 0.67-2.66 for PE and pooled RR 1.45, 95% CI, 0.93-2.77 for DVT). CONCLUSION: Our study demonstrated a significantly increased risk of VTE among HCV-infected patients. Further studies are required to clarify how this risk should be addressed in clinical practice.


Subject(s)
Blood Coagulation , Hepatitis C/epidemiology , Pulmonary Embolism/epidemiology , Venous Thromboembolism/epidemiology , Venous Thrombosis/epidemiology , Chi-Square Distribution , Female , Hepacivirus/pathogenicity , Hepatitis C/blood , Hepatitis C/diagnosis , Hepatitis C/virology , Host-Pathogen Interactions , Humans , Male , Middle Aged , Odds Ratio , Pulmonary Embolism/blood , Pulmonary Embolism/diagnosis , Pulmonary Embolism/virology , Risk Assessment , Risk Factors , Venous Thromboembolism/blood , Venous Thromboembolism/diagnosis , Venous Thromboembolism/virology , Venous Thrombosis/blood , Venous Thrombosis/diagnosis , Venous Thrombosis/virology
SELECTION OF CITATIONS
SEARCH DETAIL